COST-EFFECTIVENESS ANALYSIS OF ADJUVANTALECTINIB COMPARED TO PLATINUM-BASED ADJUVANTCHEMOTHERAPY IN PATIENTS WITH RESECTABLE ALK-POSITIVE NSCLC IN ITALY

被引：0
|
作者：
Paoletti, M. [1 ]
Scansetti, V [1 ]
Cazzato, D. [1 ]
Marcellusi, A. [2 ]
Belfiore, M. [3 ]
Isoko, J. [4 ]
Pacifici, M. [4 ]
Cortinovis, L. D. [5 ]
Veronesi, G. [6 ]
机构：
[1] Univ Roma Tor Vergata, Fac Econ, Dept Econ & Finance, Econ Evaluat & HTA EEHTA CEIS, Rome, RM, Italy
[2] Univ Milan, Milan, Italy
[3] Roche Spa, Milan, MI, Italy
[4] Roche Spa, Milan, MI, Italy
[5] Univ Milano Bicocca, Dept Med, Milan, Italy
[6] Univ Vita Salute San Raffaele, Milan, Italy
来源：
VALUE IN HEALTH | 2024年 / 27卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE459
引用
收藏
页数：2
相关论文
共 50 条
  • [31] ALECTINIB, BRIGATINIB, AND LORLATINIB AS FIRST-LINE THERAPIES FOR ADVANCED ALK-POSITIVE NON-SMALL CELL LUNG CANCER: A COST-EFFECTIVENESS ANALYSIS
    Mudumba, R.
    Nieva, J. J.
    Padula, W.
    VALUE IN HEALTH, 2024, 27 (12) : S81 - S81
  • [32] Single-agent pemetrexed in patients with ALK-positive NSCLC: A retrospective analysis of investigator-reported outcomes
    Salgia, R.
    Ou, S. I.
    Riely, G.
    Kim, D. W.
    Shaw, A.
    Wilner, K.
    Tang, Y.
    Polli, A.
    Scagliotti, G. V.
    CLINICAL CANCER RESEARCH, 2012, 18 (03)
  • [33] COST-EFFECTIVENESS OF LORLATINIB IN SECOND-LINE TREATMENT OF ALK-POSITIVE ADVANCED NON-SMALL CELL LUNG CANCER IN CHINA
    Shi, S.
    Jiang, Y.
    VALUE IN HEALTH, 2023, 26 (12) : S201 - S201
  • [34] Cost-effectiveness analysis of adjuvant therapy with atezolizumab in Chinese patients with stage IB-IIIA resectable NSCLC after adjuvant chemotherapy
    Chen, Ping
    Yang, Qing
    Li, Yinfeng
    Jing, Xiaomei
    Chen, Jing
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [35] COST-EFFECTIVENESS ANALYSIS OF CRIZOTINIB IN METASTATIC ALK plus NON-SMALL CELL LUNG CANCER (NSCLC)
    Montero, Alberto J.
    Lopes, Gilberto
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S1211 - S1212
  • [36] Neoadjuvant Alectinib in Potentially Resectable Stage III ALK-Positive NSCLC: Interim Analysis of ALNEO-GOIRC-01-2020 Phase II Trial
    Leonetti, A.
    Boni, L.
    Gnetti, L.
    Cortinovis, D. L.
    Mazzoni, F.
    Pasello, G.
    Passiglia, F.
    Bearz, A.
    Pilotto, S.
    Gelsomino, F.
    Metro, G.
    Bertolini, F.
    Toschi, L.
    Parra, H. Soto
    Delmonte, A.
    Cecere, F. L.
    Ricciardi, S.
    Bria, E.
    Tognetto, M.
    Tiseo, M.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S52 - S52
  • [37] Cost-Effectiveness of Crizotinib Versus Chemotherapy as First-Line Treatment of ALK Positive Advanced NSCLC - A Real World Study
    Huang, M.
    Tian, Y.
    He, M.
    Ren, L.
    Gong, Y.
    Peng, F.
    Wang, Y.
    Ding, Z.
    Wang, J.
    Zhu, J.
    Xu, Y.
    Liu, Y.
    Li, L.
    Lu, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S475 - S475
  • [38] COST-EFFECTIVENESS OF EML4-ALK GENE TARGETED FIRST-LINE CERITINIB TREATMENT AMONG PATIENTS WITH ADVANCED ALK-POSITIVE NON-SMALL CELL LUNG CANCER
    Upadhyay, N.
    Atreja, N.
    VALUE IN HEALTH, 2015, 18 (03) : A203 - A203
  • [39] Based on the CROWN Findings, Lorlatinib Should Be the Preferred First-Line Treatment for Patients With Advanced ALK-Positive NSCLC
    Hoe, Hui Jing
    Solomon, Benjamin J.
    JOURNAL OF THORACIC ONCOLOGY, 2025, 20 (02) : 154 - 156
  • [40] Cost-Effectiveness of Dimethyl Fumarate Compared to Teriflunomide for Relapsing Remitting Multiple Sclerosis Patients in Italy
    Mantovani, Lorenzo Giovanni
    Cortesi, Paolo Angelo
    Cardillo, Alessandra
    Santoni, Laura
    Prosperini, Luca
    FARMECONOMIA-HEALTH ECONOMICS AND THERAPEUTIC PATHWAYS, 2022, 23 (01) : 13 - 28
12345